Cost-benefit study of CXL

A 10-year treatment effect justifies CXL in progressive keratoconus

Cost-benefit study of CXL
Roibeard O’hEineachain
Roibeard O’hEineachain
Published: Tuesday, June 6, 2017
[caption id="attachment_8414" align="alignnone" width="325"]Daniel A Godefrooij MD Daniel A Godefrooij MD[/caption] Corneal crosslinking (CXL) is cost-effective in the treatment of patients with progressive keratoconus, suggests a comparison study presented at the 21st ESCRS Winter Meeting in Maastricht, The Netherlands. Using a probabilistic-type stochastic Markov-type model, the study compared two identical cohorts, each including 1,000 virtual patients with progressive bilateral keratoconus. One cohort received CXL and the other cohort received no initial intervention, said Daniel A Godefrooij MD, University Medical Center Utrecht, The Netherlands. He noted that the study modelled the patients and their virtual annual evaluations based on data from published trials and cohort studies over a lifetime. They took into account disease progression, and the probability of corneal transplantation and/or graft failure. The analysis showed that, assuming a 10-year duration of effect, CXL is cost-effective for progressive keratoconus at a willingness-to-pay threshold of €115,518, which is three times the current gross domestic product (GDP) per capita. Moreover, assuming a longer stabilising effect of CXL would increase the cost-effectiveness, Dr Godefrooij noted. “We assumed that the longest duration of crosslinking effectiveness will be 10 years, which is the longest follow-up published, but we did not see a degeneration of the crosslinking effect, so it's plausible that the effect is longer than 10 years,” he said. He noted that assuming a 10-year effect of CXL, the incremental cost-effectiveness ratio (ICER) – the difference in cost between two possible interventions divided by the difference in their effect – was €54,384 per quality-adjusted life year (QALY). However, when they adjusted the stabilising effect of CXL to have a lifelong duration, the ICER decreased to €10,149/QALY. “That means the cost of one QALY is under the per capita GDP threshold and thus very cost-effective,” he said. Dr Godefrooij noted that the ability to maximise cost-effectiveness of CXL is limited by the difficulty in determining who will benefit most from CXL and who will benefit least. Not all keratoconus patients will require keratoplasty in their lifetime, and contact lenses may be all they will ever require. “A better defined indication for crosslinking would also improve cost-effectiveness,” he added. Daniel A Godefrooij: d.a.godefrooij@umcutrecht.nl
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...